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Objectives: Our purpose was to improve the performance of carbon-coated expanded polytetrafluoroethylene vascular
grafts by bonding the grafts with silyl-heparin, a biologically active heparin analog, using polyethylene glycol as a
cross-linking agent.
Material and method: Silyl-heparin–bonded carbon-coated expanded polytetrafluoroethylene vascular grafts (Bard
Peripheral Vascular, Tempe, Ariz), were evaluated for patency and platelet deposition 2 hours, 7 days, and 30 days after
graft implantation in a canine bilateral aortoiliac artery model. Platelet deposition was determined by injection of
autologous, 111Indium-radiolabeled platelets, followed by a 2-hour circulation period prior to graft explantation.
Histologic studies were performed on a 2-mm longitudinal strip of each graft (7-day and 30-day groups). Heparin
activity of the explanted silyl-heparin grafts was determined by using an antithrombin-III based thrombin binding assay.
Results: Overall chronic graft patency (7-day and 30-day groups) was 100% for the silyl-heparin bonded (16/16) grafts
versus 68.75% for control (11/16) grafts (P  .043). Acute 2-hour graft patency was 100% for the silyl-heparin bonded
(6/6) grafts versus 83.3% for control (5/6) grafts. Radiolabeled platelet deposition studies revealed a significantly lower
amount of platelets deposited on the silyl-heparin grafts as compared with control grafts in the 30-day group (13.8 
7.18 vs 28.4 9.73, CPM per cm2 per million platelets, mean SD, P .0451, Wilcoxon rank sum test). In the 2-hour
group of dogs, a trend towards a lower deposition of platelets on the silyl-heparin grafts was observed. There was no
significant difference in platelet deposition between the two grafts in the 7-day group. Histologic studies revealed a
significant reduction in intraluminal graft thrombus present on the silyl-heparin grafts as compared with control grafts
in the 30-day group of animals. In contrast, there was no difference in amount of graft thrombus present on both graft
types in the 7-day group of dogs. Pre-implant heparin activity on the silyl-heparin bonded grafts was 2.0 IU/cm2
(international units[IU]/cm2). Heparin activity remained present on the silyl-heparin grafts after explantation at all 3
time points (2 hours: above upper limit of assay, upper limit 0.57, n 6; 7 days: 0.106 0.015, n 5; 30 days: 0.007
 0.001, n  5; mean  SD, IU/cm2).
Conclusion: Silyl-heparin bonding onto carbon-coated expanded polytetrafluoroethylene vascular grafts resulted in (1)
improved graft patency, (2) increased in vivo graft thromboresistance, and (3) a significant reduction in intraluminal graft
thrombus. This graft may prove to be useful in the clinical setting. (J Vasc Surg 2004;39:1059-65.)
Clinical Relevance: Expanded polytetrafluoroethylene (ePTFE) remains the most commonly used prosthetic graft
material in infrainguinal arterial reconstructions. Reported long-term patency rates of ePTFE bypass grafts are inferior
to those observed with autogenous vein. Modification of the luminal surface of ePTFE bypass grafts may prevent early
graft failure and ultimately improve long-term graft performance. Silyl-heparin is a biologically active heparin analog that
is readily adsorbed onto hydrophobic surfaces while retaining its anticoagulant properties. Silyl-heparin bonding onto
carbon-coated ePTFE grafts improves the patency and in vivo thromboresistance and results in a decrease in intraluminal
graft thrombus. This graft may be useful in the clinical setting.Reprint requests: Howard P. Greisler, MD, Division of Peripheral Vas-
cular Surgery, Department of Surgery, Loyola University Medical
Center, 2160 South First Avenue, Maywood, IL 60153 (e-mail:
hgreisl@lumc.edu).
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cedures are performed in the United States each year.1 The
majority of these operations are infrainguinal reconstruc-
tions done for critical limb ischemia and limb salvage.
Autogenous vein remains the conduit of choice. However,
in situations where vein is unsuitable or unavailable, pros-
thetic graft material is utilized. Expanded polytetrafluoro-
ethylene (ePTFE) remains the most commonly used pros-
thetic graft material in infrainguinal arterial reconstructions.
Although reported long-term patency rates of ePTFE bypass
grafts are inferior to those observed with autogenous vein,2
modification of the luminal surface of ePTFE bypass
grafts may prevent early graft failure and ultimately
improve long-term graft performance.
Silyl-heparin is a biologically active heparin analog that
is readily adsorbed onto hydrophobic surfaces while retain-
ing its anticoagulant properties. We recently reported our
experience with a silyl-heparin adsorbed, carbon-coated
ePTFE graft, where an improvement in graft thrombore-
sistance was observed.3 The advantage in thromboresis-
tance, however, was short-lived due to poor retention of
the heparin analog on the grafts. We have successfully
bonded silyl-heparin onto carbon-coated ePTFE grafts,
significantly improving its retention. We now report our
experience with a silyl-heparin bonded, carbon-coated
ePTFE graft.
MATERIAL AND METHODS
Grafts. Control grafts were carbon-coated, 4-mm in-
ternal diameter, 5-cm-long ePTFE, 30-m internodal dis-
tance, without outer support. Experimental grafts were
control grafts that underwent silyl-heparin bonding. All
grafts were supplied by Bard Peripheral Vascular, Tempe,
Ariz. Briefly, grafts were wetted by immersion in acetone
and transferred to an acetonitrile solution containing 0.5
mg/mL of bis (benzotriazole carbonate)-polyethylene gly-
col (BTC-PEG) (Nektar Therapeutics, San Carlos, Calif)
for 30 minutes. The grafts were then immersed in 60%
acetonitrile solution containing 1% silyl-heparin (benzyl-
tetra[dimethylsilylmethyl]oxycarbamoyl-heparin) for 1
hour and reimmersed a BTC-PEG solution for 30 minutes.
The grafts were rinsed in several changes of acetonitrile and
air-dried at 56oC. All grafts were ethylene-oxide sterilized.
Grafts were evaluated for patency and platelet deposition 2
hours, 7 days, and 30 days after graft implantation in a
canine bilateral aortoiliac artery model.
Animal model. Adult mongrel dogs (19-26 kg) were
obtained from a local supplier and underwent standard
preoperative evaluation, which included platelet aggre-
gometry as previously described,4 and laboratory measure-
ment of prothrombin time, activated partial thromboplas-
tin, and complete blood count. All dogs displayed
nonaggregator profiles, and all laboratory measurements
were consistent with normal controls. All dogs were med-
icated with 81-mg acetylsalicylic acid daily and 25-mg
dipyridamole three times a day for 3 days before operation.Both medications were continued postoperatively in keep-
ing with our standard protocols for long-term canine im-
plants.4 Platelet aggregometry was repeated on the day of
surgery, and all dogs remained nonaggregators.
After an overnight fast, the dogs were anesthetized with
IV thiopental sodium (30 mg/kg), intubated, and venti-
lated. Perioperative cefazolin (500 mg IV) was given after
induction and 4 hours later in both the 7-day and 30-day
groups of dogs. Anesthesia was maintained with nitrous
oxide and isoflurane. Exposure of the infrarenal aorta and
iliac arteries was obtained through a midline incision. The
infrarenal aorta, its branches, and iliac arteries were dis-
sected, and the median sacral artery was ligated and divided.
Heparin (100 IU/kg) was given 5 minutes before clamping
of the aorta and iliac vessels. Bilateral aortoiliac grafting was
then performed, with one experimental and one control
graft placed on either (alternating) side of the dog. Graft
anastomoses were performed with a continuous 6-0
polypropylene suture (on a BV-1 needle) proximally in an
end-to-side fashion on the aorta and distally in an end-to-
end fashion with the common iliac arteries. The transected
proximal common iliac arteries were ligated. Unclamping
and exposure to blood was identical for both experimental
and control grafts.
Blood flows through the iliac arteries were quantitated
immediately before aortic and iliac artery clamping and 5
minutes after unclamping with an electromagnetic flowme-
ter (model SP2204, Gould Inc, Medical Products Division,
Oxnard, Calif) to document the absence of technical or
hemodynamic differences affecting results. Pre-implanta-
tion and post-implantation iliac flows were symmetrical in
all animals.
In the acute 2-hour group of animals, 111Indium-
labeled autologous platelets were injected intravenously 10
minutes before aortic and iliac artery unclamping. Circula-
tion was re-established through both grafts simultaneously
and maintained for 120 minutes prior to explantation.
Six dogs were used in the acute studies (2-hour group
of animals) and 16 dogs in the chronic studies (both the 7-
and 30-day groups). Animal care complied with the “Prin-
ciples of Laboratory Animal Care” and “The Guide for the
Care and Use of Laboratory Animals.”5
Graft explantation. In the acute 2-hour group of
animals, another dose of heparin (100 IU/kg) was given 5
minutes before reclamping of the aorta and iliac arteries
after the 120-minute circulation period. In both the 7-day
and 30-day groups, where both control and experimental
grafts were patent, dogs were anesthetized as described.
Radiolabeled platelets were injected intravenously followed
by a 120-minute circulation period. At 90 minutes, the
infrarenal aorta and iliac arteries were dissected. Heparin
(100 IU/kg) was given 5 minutes before clamping of the
aorta and iliac arteries. Pre-explantation iliac artery flows
were quantitated as described, and flows were found to be
symmetrical in all animals.
Grafts were explanted in continuity, with 2- to 3-cm
segments of aorta and iliac arteries that had not been
clamped. Dogs were euthanized with a lethal dose of IV
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the aorta and iliac arteries and immersed in normal saline to
remove any external blood. The specimens were flushed of
luminal blood with normal saline through the aortic open-
ing (20 mL) and through both iliac artery openings (10 mL
each). Both proximal and distal anastomoses were taken
down, and each explanted graft was opened longitudinally
along the inferior aspect. Explanted grafts were then cut
into five 1-cm-long segments, which were numbered 1 to 5
starting at the distal end and were measured for radioactiv-
ity by a gamma radiation counter (Packard Auto Gamma
5650, Packard Instrument Co, Downers Grove, Ill). Seg-
ments were then photographed with a digital camera (Ni-
kon Coolpix 5700, Nikon Corp, Tokyo, Japan), to allow
for surface area determination by computerized planimetry
(Scion Image 4.0, Scion Corp, Frederick, Md). Graft seg-
ment radioactivity was expressed as count per minute
(CPM). Total graft radioactivity was normalized to graft
surface area and number of platelets injected and was
expressed as CPM per cm2 per million platelets injected.
Radiolabeling of platelets. Canine autologous plate-
lets were labeled with radioactive 111Indium as previously
described.4 Briefly, on the day of explantation 86 mL of
blood was collected by jugular puncture and mixed with 14
mL of acid-citrate-dextrose anticoagulant solution, fol-
lowed by isolation of platelet-rich plasma by centrifugation
(200 g, 30 minutes). Platelets were pelletized by centrif-
ugation (650  g, 10 minutes) and then resuspended in
normal saline and incubated at 37o C for 10 minutes with
800 Ci of radioactive 111Indium oxyquinoline solution
(Amersham Healthcare, Arlington Heights, Ill). After re-
centrifugation, the pellet was washed with 2 mL of normal
saline and then suspended in 7 mL of normal saline/acid-
citrate-dextrose solution. 111Indium radiolabeling effi-
ciency was on the order of 88% to 97%.
Histologic analysis of grafts. Histologic analysis was
performed on explanted grafts from the 7-day and 30-day
groups. The acute group of explanted grafts did not un-
dergo histologic evaluation because microscopic differ-
ences observed within a 2-hour implantation are negligible.
The carbon coating on the ePTFE grafts made thrombus-
free surface area determinations problematic; therefore,
histologic analysis was performed on a 2-mm-wide longi-
tudinal strip of graft taken at the time of explantation. The
strip of graft was excised from the inferior edge of the graft
starting at the heel of the proximal anastomosis and extend-
ing distally. The strip of graft was then fixed in 4% parafor-
maldehyde and stained with hematoxylin and eosin, after
subsequent decay of radioactivity. Photomicrographs were
taken of stained graft segments, and histologic parameters
were determined by computerized planimetry (Scion Im-
age 4.0, Scion Corp, Frederick, Md). To avoid sample bias,
the histologist was blinded to both group of animals and
graft type. Histologic parameters measured were graft
length, thrombus length, thrombus area, and maximal
thrombus height. From these measurements, the percent-
age of graft length free of thrombus could be calculated(graft length–thrombus length/graft length 100) as well
as average height of thrombus (area of thrombus/throm-
bus length).
Heparin activity of grafts. The heparin activity of the
silyl-heparin–coated grafts was determined by using an
anti-thrombin III–based thrombin binding assay that was
modified from one previously described.6 The assay utilizes
a defined concentration of antithrombin III and thrombin
in excess. In the assay, antithrombin III binds with heparin.
The resulting heparin–antithrombin III complex then
binds and inactivates thrombin. Residual thrombin is
free to react with the chromogenic substrate S2238
(DiaPharma, West Chester, Ohio), liberating a chro-
mophore that absorbs at 405 nanometers.
A 1-cm segment of silyl-heparin graft was placed in an
Eppendorf tube containing 700 L of HEPES buffer
(25mmol/L HEPES, 190 mmol/L NaCl, 0.5 mg/mL
bovine serum albumin, pH 7.5). Antithrombin III (DiaP-
harma), 100 L , (2 international units [IU]/mL in dis-
tilled water) was then added followed by thrombin (Amer-
ican Red Cross, Washington, DC), 200 L, (10 IU/mL in
0.9% NaCl). The reaction tube was agitated at room tem-
perature for 3 minutes. An aliquot (20 L) of the graft–
antithrombin III–thrombin solution was then taken and
added to 380 L of Tris-EDTA buffer (50-mmol/L Tris
Base, 175-mmol/L NaCl, 7.5-mmol/L Na2EDTA, pH
8.4). To this solution, 100 L of S2238 (2 nmol/L in
sterile water) was then added. After 3 minutes at 37oC, 300
L of 20% acetic acid was added to stop the chromogenic
reaction. An aliquot (200 L) of the final solution was
placed in a 96-well microtiter plate, and the absorption of
the solution at 405 nanometers was read on a Bio-Tek
EL800 (Bio-Tek Instruments Inc, Winooski, Vt) microti-
ter plate reader. A heparin standard curve was generated by
incubating heparin (Upjohn, Kalamazoo, Mich) at various
concentrations (range, 0.005-0.02 IU/mL) with anti-
thrombin III and thrombin. An aliquot (20 L) of each
solution was then assayed as previously described. The
upper limit of the assay was 0.57 IU per cm2 of graft.
Intra-assay and interassay coefficients of variation were less
than 10%.
Heparin activity of silyl-heparin grafts was measured
before and after explant. Heparin activity was expressed in
IU per cm2 of graft.
Statistical analysis. Statistical comparisons of platelet
deposition within each group (acute 2-hour, 7-day, and
30-day), were performed between silyl-heparin adsorbed
grafts and control grafts by using the nonparametric Wil-
coxon rank sum test. The Fisher exact test was used for
statistical comparisons of patency within each group (acute
2-hour, 7-day, and 30-day) between both graft types. All
statistical tests were performed on a computer using the
Statview statistical software program for the Wilcoxon rank
sum test (SAS Institute, Cary, NC) and the SISA Fisher
exact test Internet program.7 Data are presented as mean
standard deviation.
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The silyl-heparin bonded grafts were indistinguishable
from the control carbon-coated vascular grafts in appear-
ance during implantation. Surgeons were blinded at the
time of operation as to the side to which either graft was
assigned. Graft handling characteristics—namely stiffness,
ability to hold sutures, and pliability—were similar between
the silyl-heparin bonded and control carbon-coated grafts.
Suture hole bleeding was problematic in the silyl-heparin
bonded grafts, which required multiple applications of
oxidized regenerated cellulose (Surgicel, Johnson and
Johnson, New Brunswick, NJ) to the proximal suture line
for up to 90 minutes and to the distal suture line for up to
60 minutes before cessation of bleeding. Oxidized regen-
erated cellulose was removed after hemostasis was achieved.
In contrast, suture hole bleeding was minimal in the con-
trol grafts.
In the acute 2-hour group of dogs, patency was 100%
(6/6) for silyl-heparin and 83.3% (5/6) for control grafts.
This difference was not significant as measured by the
Fisher exact test (P  .50). Overall chronic 7-day and
30-day graft patency was 100% for the silyl-heparin bonded
(16/16) grafts versus 68.75% for control (11/16) grafts.
This difference was statistically significant (P  .043). All
control graft occlusions occurred within the first postoper-
ative day, as determined by loss of palpable femoral pulses
on physical examination of the animals. All grafts (both
patent and occluded) were explanted, and both proximal
and distal anastomoses were examined. No technical errors
were observed in any of the explanted grafts. In addition,
no hematomas or seromas were noted postoperatively.
111Indium-radiolabeled platelet studies were per-
formed only in dogs in which both experimental and con-
trol grafts were patent. A linear relationship between total
number of platelets injected and total graft radioactivity was
observed (data not shown). Therefore, the total radioactiv-
ity of each graft was normalized to both graft surface area
and number of platelets injected (Table I). In the acute
2-hour group of animals, a lower amount of radiolabeled
platelets was deposited on the silyl-heparin bonded grafts
than on the control grafts (3.32  2.42 vs 40.1  58.1
CPM per cm2 per million platelets injected, mean  SD).
This difference did not reach statistical significance. In the
7-day group of dogs, there was a trend towards a higher
amount of radiolabeled platelets deposited on the silyl-
heparin bonded grafts (although not statistically signifi-
cant) compared with control grafts. In the 30-day group of
Table I. 111Indium radiolabeled platelet deposition
Group Control grafts Silyl-heparin grafts
2-Hour 40.1  58.1 3.32  2.42
7-Day 13.9  22.2 21.8  12.1
30-Day* 28.4  9.73* 13.8  7.18*
Counts per minute per cm2 per million platelets injected, mean  SD, n 
5.
*P  .0451, Wilcoxon rank sum test.animals, a significantly lower amount of platelets was de-
posited onto the silyl-heparin bonded grafts compared with
control grafts (P  .0451, Wilcoxon rank sum test).
Histologic analysis of grafts revealed a significantly
lower amount of intraluminal thrombus on the silyl-hepa-
rin bonded grafts than on control grafts in the 30-day
group of animals. This was consistent in all histologic
parameters measured, including graft percentage free of
thrombus (Figs 1 and 2). In contrast, there was no differ-
ence in the amount of intraluminal thrombus observed on
both types of grafts in the 7-day group of dogs (Figs 1 and
2).
Based on calculations obtained during the bonding
process, the pre-implant activity of the silyl-heparin bonded
grafts was estimated to be 2.0 IU per cm2 of graft (Table
II). After a 2-hour implantation, the activity of the silyl-
heparin bonded grafts remained above the upper limit of
the heparin assay (0.57 IU per cm2 of graft). After 7 days
implanted, the activity decreased to 0.106  0.015 IU per
cm2 of graft (5.3% of pre-implant activity). The activity of
the silyl-heparin bonded grafts further decreased, after 30
days implanted, to 0.007  0.001 IU per cm2 of graft
(0.35% of pre-implant activity).
DISCUSSION
In order to improve surface hemocompatibility, hepa-
rin has been immobilized onto the blood-contact surface of
numerous medical devices such as coronary stents, cardio-
pulmonary bypass circuits, ventricular assist devices, and
central venous catheters.8-11 Biologically active heparin has
been immobilized onto Dacron and ePTFE vascular
grafts.12-14 The heparin-bonded Dacron graft, intended
primarily for infra-inguinal arterial reconstruction, has been
available clinically for the past several years. The results of a
randomized clinical trial comparing the heparin-bonded
Dacron graft with ePTFE grafts in femoropopliteal artery
bypass grafting have recently been reported, in which an
advantage in 3-year graft patency and 3-year amputation
rate was observed with the heparin-bonded Dacron graft
over the ePTFE grafts.11 The heparin ePTFE graft was
recently evaluated in a canine carotid artery interposition
grafting model where improved patency and thromboresis-
tance were observed.14
Carbon coating of ePTFE vascular grafts has been
shown to decrease surface thrombogenicity due to its neg-
ative charge and hydrophobic nature. Carbon-coated pros-
thetic grafts were shown to reduce platelet deposition.15 In
Table II. Heparin activity of silyl-heparin bonded grafts
Silyl-heparin grafts IU/cm2  SD
Pre-implant 2.0
Acute 2 hour (n  6) 0.57*
7-Day (n  5) 0.106  0.015
30-Day (n  5) 0.007  0.001
Iu, International units.
*Upper limit of assay.
ilcox
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patency and higher 12-month limb salvage rates have been
reported in a multicenter clinical trial.16
Surface modification using hydrophilic polymers effec-
tively prevents protein adsorption and cell adhesion.17-19
Fig 1. Histologic parameters measured in silyl-heparin an
summarized. A, Graft thrombus length. B, Graft average
of graft thrombus (n  5, mean  SD, P  .0451 by W
Fig 2. The percentage of silyl-heparin and control graft
groups of dogs (n  5, mean  SD, P  .0451 by WilcPolyethylene glycol (PEG) has been extensively used for
surface modification because of its unique properties, such
as hydrophilicity, flexibility, nontoxicity, and non-immu-
nogenicity.20 When coated on hydrophobic surfaces, PEG
has been shown to decrease protein adsorption and platelet
ntrol grafts for both chronic 7-day and 30-day groups are
bus height. C, Graft thrombus area. D, Maximal height
on rank sum test).
h free of thrombus is shown for both 7-day and 30-day
rank sum test).d co
thromlengt
oxon
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lant activities, such as tissue factor expression and Factor Xa
generation by monocytes, have been shown to be reduced
on PEG-coated polystyrene versus uncoated polystyrene.22
In contrast, PEG immobilization onto ePTFE resulted,
according to one report, in an increase in surface platelet
adhesion.20 Despite the increase in platelet adhesion, the
PEG-coated ePTFE surface demonstrated improved blood
compatibility (increased albumin adsorption and decreased
fibrinogen adsorption).20
Silyl-heparin, benzyl-tetra(dimethylsilylmethyl)oxy-
carbamoyl-heparin, is a biologically active heparin analogue
synthesized by conjugating silyl-prosthetic units to the
heparin molecule. The resultant molecule is amphipathic
and readily adsorbed onto hydrophobic surfaces and bio-
degradable polymers, while retaining its anticoagulant
properties. We have recently evaluated a silyl-heparin ad-
sorbed carbon-coated ePTFE graft in a canine aortoiliac
model where a significant improvement in thromboresis-
tance was observed.3 The advantage in thromboresistance,
however, was short-lived due to poor retention of the
silyl-heparin on the carbon-coated ePTFE grafts. In the
present study, we have improved the retention of the
silyl-heparin by using polyethylene glycol to bond the
molecule onto the grafts and by increasing the total amount
of active silyl-heparin present on the grafts by tenfold.
Heparin assay of the explanted silyl-heparin grafts con-
firmed the presence of active silyl-heparin up to 30 days
post implantation (Table II).
Silyl-heparin bonding onto carbon-coated ePTFE
grafts resulted in a significant improvement in graft patency
and thromboresistance (Table I). The advantage in silyl-
heparin graft thromboresistance, as measured by reduced
platelet deposition, reached statistical significance at 30
days. A significant reduction in intraluminal graft thrombus
in the silyl-heparin bonded grafts was also observed in the
30-day group of animals (Fig 1 and 2). In the 7-day group
of dogs, there was no difference in platelet deposition or the
amount of intraluminal graft thrombus present on the
silyl-heparin bonded grafts compared with control grafts.
In the acute 2-hour group of animals, a reduction in
platelet deposition was observed in the silyl-heparin
bonded grafts compared with control grafts, although this
difference was not statistically significant. These findings
support a time-dependent mechanism for the development
of a thromboresistant surface on the silyl-heparin bonded
grafts.
The lack of advantage in thromboresistance observed in
the 7-day group of animals is possibly due to a combination
of time-dependent PEG and silyl-heparin effects that result
in a delay in initial surface platelet deposition measured at
the 7-day time point. The silyl-heparin bonding process is
such that the heparin analog is sandwiched between two
separate applications of PEG to the carbon-coated ePTFE
grafts (see Material and Methods).
From a theoretical standpoint, the initial silyl-heparin–
mediated advantage in thromboresistance observed in the
acute 2-hour group would lead to a delay in the accumula-tion of coagulant proteins such as thrombin and Factor Xa
on the luminal surface after graft implantation. Thrombin
and Factor Xa have been shown to contribute to graft-
associated procoagulant activity.23 The delay in the accu-
mulation of these coagulant proteins would allow deposi-
tion of less thrombogenic proteins, such as albumin and
immunoglobulin G, and formation of a hemocompatible
surface.24 In addition, the PEG-mediated attenuation of
leukocyte-induced procoagulant effects would further con-
tribute to surface thromboresistance.22 By 7 days, when
only 5% of the initial silyl-heparin remains, the PEG and
silyl-heparin effects result in an increase in measured plate-
let deposition (Table II). Although an increase in platelet
deposition is observed, improved blood compatibility re-
mains. After this time, a passivated surface would be
present, resulting in lower intraluminal thrombus accumu-
lation and lower platelet deposition. At 30 days, only 0.35%
of the silyl-heparin remains on the experimental graft sur-
face. At this time, the silyl-heparin effect is less important, as
evidenced by the small amount remaining compared with
the additive or synergistic effect of both PEG and silyl-
heparin. This process may prevent early graft failure leading
ultimately to improved long-term graft patency rates.
In conclusion, silyl-heparin bonding onto carbon-
coated ePTFE grafts resulted in an increase in graft patency,
improved thromboresistance, and a significant reduction in
intraluminal graft thrombus. This graft may prove to be
useful in the clinical setting.
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